Eric So Acquires 100,000 Shares of Cybin (NASDAQ:HELP) Stock

Cybin Inc. (NASDAQ:HELP) insider Eric So bought 100,000 shares of the company’s stock in a transaction on Friday, September 4th. The shares were acquired at an average price of $12.09 per share, with a total value of $1,209,000.00. Following the completion of the acquisition, the insider directly owned 4,365,014 shares in the company, valued at $52,773,019.26. This represents a 2.34% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Cybin Stock Performance

Cybin stock opened at $12.97 on Friday. The stock has a fifty day moving average of $9.97 and a two-hundred day moving average of $6.89. The company has a market capitalization of $980.66 million, a price-to-earnings ratio of -4.29 and a beta of 0.63. Cybin Inc. has a fifty-two week low of $3.76 and a fifty-two week high of $14.35.

Cybin (NASDAQ:HELP) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). On average, analysts forecast that Cybin Inc. will post -2.95 EPS for the current fiscal year.

More Cybin News

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: Insider Paul Glavine bought 100,000 shares for approximately $1.25 million on September 8, increasing his direct ownership by 2.40%. Insider Eric H. L. So also purchased 100,000 shares for about $1.24 million, lifting his stake by 2.29%. These transactions follow additional purchases by both insiders in late August and early September, representing a notable pattern of open-market buying and likely supporting investor confidence. Eric So SEC filing Paul Glavine SEC filing
• Positive Sentiment: Cybin’s commercial operations are scheduled to receive investor exposure at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. CEO Michael Halstead is expected to participate in a fireside chat, potentially providing updates on the company’s psychedelic-based mental-health drug pipeline. Morgan Stanley conference announcement
• Neutral Sentiment: Reported short interest was zero shares with a zero-day days-to-cover ratio. However, the filing also showed an invalid “NaN” percentage change, making the data unreliable as an indicator of short-selling pressure.
• Negative Sentiment: Cybin remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.91 per share was worse than the expected $0.80 loss, and analysts project a full-year loss of approximately $2.95 per share. With no new trial result or regulatory approval reported, valuation and future financing needs remain important risks after the stock’s sharp advance.

Hedge Funds Weigh In On Cybin

Large investors have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its stake in Cybin by 1,388.5% in the 4th quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after buying an additional 959,448 shares during the last quarter. Pale Fire Capital SE acquired a new position in shares of Cybin during the 2nd quarter valued at about $1,015,000. Bank of America Corp DE lifted its holdings in shares of Cybin by 66.8% during the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after acquiring an additional 11,790 shares during the period. AXQ Capital LP purchased a new position in shares of Cybin during the 2nd quarter worth about $75,000. Finally, Osaic Holdings Inc. boosted its position in shares of Cybin by 46.7% in the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock worth $63,000 after acquiring an additional 2,400 shares during the last quarter. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Wells Fargo & Company initiated coverage on shares of Cybin in a report on Monday, July 27th. They set an “overweight” rating and a $16.00 price target for the company. TD Cowen upped their price objective on shares of Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Finally, Wall Street Zen upgraded shares of Cybin from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $48.60.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.